Neoplasms, Unknown Primary Clinical Trial
Official title:
A Randomised Phase III Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With Carcinoma of an Unknown Primary (CUP)
This is a european randomised, phase III, multi-centric study comparing a diagnostic and therapeutic strategy based on molecular analysis followed by suspected primary cancer tailored specific therapy, to an empiric strategy in patients with carcinoma of unknown primary. The purpose of this trial is to determine whether or not a strategy based on molecular analysis is effective in improving the progression free survival rates of patients with carcinoma of unknown primary (CUP).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04025970 -
Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUP
|
||
Completed |
NCT00193609 -
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
|
Phase 2 | |
Completed |
NCT00193596 -
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
|
Phase 3 | |
Completed |
NCT02628379 -
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
|
||
Completed |
NCT01202786 -
Cost-effectiveness Study of miRviewâ„¢ Mets in Patients With Cancer of Unknown Primary (CUP)
|
N/A | |
Not yet recruiting |
NCT00894569 -
Paclitaxel/Carboplatin With or Without Cetuximab in CUP
|
Phase 2 | |
Completed |
NCT00193622 -
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
|
Phase 2 |